* hospitalized or expected to be hospitalized within 24 hours of enrollment * psychiatric or cognitive illness or recreational drug/alcohol use that in the opinion of the principal investigator, would affect subject safety and/or compliance * history of prior reactions to transfusion blood products * inability to complete therapy with the study product within 24 hours after enrollment * receiving any treatment drug for covid-19 within 14 days prior to screening evaluation (monoclonal antibodies, compassionate use or study trial related). steroid treatment at any time does not affect study eligibility

* hospitalized or expected to be hospitalized within 24 hours of enrollment * psychiatric or cognitive illness or recreational drug/alcohol use that in the opinion of the principal investigator, would affect subject safety and/or compliance * history of prior reactions to transfusion blood products * inability to complete therapy with the study product within 24 hours after enrollment * receiving any treatment drug for covid-19 within 14 days prior to screening evaluation (monoclonal antibodies, compassionate use or study trial related). steroid treatment at any time does not affect study eligibility

hospitalized or expected to be hospitalized within 24 hours of enrollment psychiatric or cognitive illness or recreational drug/alcohol use that in the opinion of the principal investigator, would affect subject safety and/or compliance history of prior reactions to transfusion blood products inability to complete therapy with the study product within 24 hours after enrollment receiving any treatment drug for covid-19 within 14 days prior to screening evaluation (monoclonal antibodies, compassionate use or study trial related). steroid treatment at any time does not affect study eligibility

hospitalized or expected to be hospitalized within 24 hours of enrollment psychiatric or cognitive illness or recreational drug/alcohol use that in the opinion of the principal investigator, would affect subject safety and/or compliance history of prior reactions to transfusion blood products inability to complete therapy with the study product within 24 hours after enrollment receiving any treatment drug for covid-19 within 14 days prior to screening evaluation (monoclonal antibodies, compassionate use or study trial related). steroid treatment at any time does not affect study eligibility

- hospitalized or expected to be hospitalized within 24 hours of enrollment - psychiatric or cognitive illness or recreational drug/alcohol use that in the opinion of the principal investigator, would affect subject safety and/or compliance - history of prior reactions to transfusion blood products - inability to complete therapy with the study product within 24 hours after enrollment - receiving any treatment drug for covid-19 within 14 days prior to screening evaluation (off label like hydroxychloroquine, compassionate use or study trial related)

- hospitalized or expected to be hospitalized within 24 hours of enrollment - psychiatric or cognitive illness or recreational drug/alcohol use that in the opinion of the principal investigator, would affect subject safety and/or compliance - history of prior reactions to transfusion blood products - inability to complete therapy with the study product within 24 hours after enrollment - receiving any treatment drug for covid-19 within 14 days prior to screening evaluation (off label like hydroxychloroquine, compassionate use or study trial related)